BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26209327)

  • 1. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.
    Bauman TM; Ewald JA; Huang W; Ricke WA
    BMC Cancer; 2015 Jul; 15():549. PubMed ID: 26209327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
    Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
    Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
    Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD147 is associated with prostate cancer progression.
    Zhong WD; Liang YX; Lin SX; Li L; He HC; Bi XC; Han ZD; Dai QS; Ye YK; Chen QB; Wang YS; Zeng GH; Zhu G; Zhang Z; Chen ZN; Wu CL
    Int J Cancer; 2012 Jan; 130(2):300-8. PubMed ID: 21328337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy.
    Bi XC; Liu JM; Zheng XG; Xian ZY; Feng ZW; Lou YX; Zhong WD; Wu CL
    Clin Invest Med; 2011 Dec; 34(6):E358. PubMed ID: 22129926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
    Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
    Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
    J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of micro-lymphatic invasion and pathological Gleason score in prostate cancer patients with pathologically organ-confined disease and negative surgical margins after robot-assisted radical prostatectomy.
    Hashimoto T; Nakashima J; Inoue R; Komori O; Yamaguchi Y; Kashima T; Satake N; Nakagami Y; Namiki K; Nagao T; Ohno Y
    Int J Clin Oncol; 2020 Feb; 25(2):377-383. PubMed ID: 31673831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.
    Chromecki TF; Cha EK; Pummer K; Scherr DS; Tewari AK; Sun M; Fajkovic H; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
    BJU Int; 2012 Jul; 110(1):63-8. PubMed ID: 22077633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight Protein Tyrosine Phosphatase Is a Possible Biomarker for Predicting Postoperative Biochemical Recurrence in Prostate Cancer With Negative Surgical Margins.
    Kurose H; Ueda K; Kondo R; Ogasawara S; Kusano H; Sanada S; Naito Y; Akiba J; Kakuma T; Igawa T; Yano H
    Anticancer Res; 2019 Feb; 39(2):957-964. PubMed ID: 30711981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
    Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
    Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.